About US
Contact us
-
Aviragen, Vaxart merge to develop oral vaccines for influenza, norovirus and RSVFor some antigens like norovirus and RSV, there are no approved vaccines. For others, like the seasonal flu, immunization rates are often far from ideal. Now, a new company, the product of a merger be2017/10/27
-
Sanofi inks AI pact to learn more about flu vaccine responsesPersonalized vaccines are mostly used in cancer, but what about prophylactic vaccines against infectious diseases? Sanofi Pasteur has tapped Berg's artificial intelligence capabilities to discover bio2017/10/27
-
Roche pulls cancer drug from Greece in fight over government cost cutsSwiss drugmaker Roche has pulled a cancer drug from the Greek market as it does battle again with authorities in the financially exhausted country over steps they have taken against drug prices in an2017/10/26
-
AstraZeneca nets lightning-fast lymphoma nod for Imbruvica rival CalquenceAbbVie and Johnson & Johnson got a scare this Halloween, and it came in the form of an FDA approval for AstraZeneca’s Imbruvica rival. Tuesday, the FDA greenlighted BTK inhibitor Calquence as a2017/10/26
-
Mylan President Rajiv Malik targeted as states expand price fixing suit against top drugmakersMylan President Rajiv Malik and Emcure CEO Satish Mehta were named individually in a vastly expandedcivil lawsuitovergeneric price fixingbrought by nearly every state in the country. The price fixing2017/10/25
-
Don't count out a consumer spinoff, Pfizer execs say amid Q3 M&A grillingIn the opening remarks of Tuesday’s Q3 earnings conference call, Pfizer CEO Ian Read offered up prescription trends and launch details on the company’s key products, including cancer treatments Ibranc2017/10/25
-
Roche discount wins Tecentriq first-in-class NICE backing for bladder cancerRoche's Tecentriq first hit the market as a bladder cancer therapy last year, but new data havesincefailed to prove it can extend those patients' lives. Thatdidn't stop England's cost-effectiveness wa2017/10/24
-
Undeterred by Pfizer's looming OTC sale, Merck KGaA scouts consumer health biddersIf you thought Merck KGaA would press pause on selling its consumer healthunit until Pfizer’s was off the market, think again. The German drugmaker this week started reaching out to prospective buy2017/10/24
-
Novartis seeks Kymriah nod in lymphoma, setting up Gilead CAR-T showdownCutting-edge cell therapies from Novartis and Gilead Sciences aren't direct competitors for now, but that could change—and soon. The Swiss drugmaker's Kymriah is now up for an FDA approval in diffus2017/10/23
-
Samsung reports operating profit, extends collaboration with Merck KGaAThree years into a manufacturing collaboration, Germany’s Merck KGaA and South Korea’s Samsung BioLogics have decided to deepen their relationshipeven as Samsung reported an operating profit for the f2017/10/23